Register Login
Register to leave comments
  • News bot Oct. 1, 2025, 3:38 p.m.

    📋 BOLT BIOTHERAPEUTICS, INC. (BOLT) - Financial Results

    Filing Date: 2022-05-12

    Accepted: 2022-05-12 16:07:16

    Event Type: Financial Results

    Event Details:

    Bolt Biotherapeutics Inc (BOLT) Reports Q2 2022 Financial Results Bolt Biotherapeutics Inc (BOLT) announced its financial results for the period ending Q2 2022. Key Financial Highlights:
    • Revenue: (51
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 45586
      • 1001 monotherapy and OPDIVO® combination trials progressing toward data readouts in second half of 2022 – Cash balance of $
      • 8 million expected to fund key milestones and operations into 2024 REDWOOD CITY, CA, May 12, 2022 – Bolt Biotherapeutics, Inc. (NASDAQ: BOLT), a clinical
      • stage biotechnology company pioneering a new class of immuno
        • targeting Boltbody ISAC in an ongoing Phase 1/2 clinical trial enrolling patients with HER2-expressing solid tumors. Bolt is also advancing BDC-2034
        • targeting immune- stimulating antibody conjugate (ISAC), is being evaluated in dose escalation as a monotherapy and in combination with OPDIVO® in an ongoing multi-center, multi-dose Phase 1/2 clinical trial. To date, BDC-1001
        • anticipated in the forward-looking statements, even if new information becomes available in the future. Further information on factors that could cause actual results to differ materially from the results anticipated by our forward-looking statements is included in the reports we have filed or will file with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2021

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Operating Expenses Loss From Operations 23.88K 18.43K $5.45K +29.58%
    Other Income Expense Net Total Other Income Expense 198.00 6.03K $-5.83K -96.72%
    Other Income Expense Net Net Loss 23.68K 24.45K $-776.00 -3.17%
    Other Income Expense Net Net Loss Per Share 0.64 1.14 $-0.50 -43.86%
    Current Assets Prepaid Expenses Other Current Assets 5.19K 2.94K $2.25K +76.37%
    Current Assets Property Equipment Net 6.64K 6.16K $479.00 +7.78%
    Current Assets Operating Lease Right Of Use Assets 23.27K 24.45K $-1.17K -4.79%
    Current Assets Other Assets 916.00 1.04K $-126.00 -12.09%
    Current Liabilities Accounts Payable 4.45K 3.57K $872.00 +24.40%
    Current Liabilities Operating Lease Liabilities 2.06K 2.50K $-440.00 -17.59%
    Current Liabilities Other Long Term Liabilities 204.00 210.00 $-6.00 -2.86%
    Cash Flows From Operating Activities Net Loss 23.68K 24.45K $-776.00 -3.17%
    Changes In Operating Assets And Liabilities Prepaid Expenses Other Current Assets 2.12K 1.35K $769.00 +56.92%
    Changes In Operating Assets And Liabilities Operating Lease Liabilities 982.00 66.00 $916.00 +1387.88%
    Changes In Operating Assets And Liabilities Other Long Term Liabilities 4.00 2.00 $2.00 +100.00%
    Loss from Operations 23.88K 18.43K $5.45K +29.58%
    Interest Income 198.00 56.00 $142.00 +253.57%
    Total Other Income/(Expense) 198.00 6.03K $-5.83K -96.72%
    Net Loss 23.68K 24.45K $-776.00 -3.17%
    Prepaid Expenses and Other Current Assets 5.19K 2.94K $2.25K +76.37%
    Property and Equipment, Net 6.64K 6.16K $479.00 +7.78%
    Other Assets 916.00 1.04K $-126.00 -12.09%
    Accounts Payable 4.45K 3.57K $872.00 +24.40%
    Revenue 3.45K 2.87K $579.00 +20.18%
    Operating Lease Liabilities 2.06K 2.50K $-440.00 -17.59%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Bolt Biotherapeutics Inc
    • CIK: 0001641281
    • Ticker Symbol: BOLT
    • Period End Date: 2022-05-12
    • Document Type: 8-K

Search

News categories